Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Gastrointestinal 1CNS 1

Conditions

Neoplasms 1Leukemia, Myeloid, Acute 1Glioma 1Cholangiocarcinoma 1

Interventions

Specimen Handling 80Fluorouracil 75Oxaliplatin 67Magnetic Resonance Spectroscopy 61Leucovorin 59Bevacizumab 56Gemcitabine 53Biopsy 41Irinotecan 37Capecitabine 37pembrolizumab 35Cisplatin 35Nivolumab 33Cetuximab 32130-nm albumin-bound paclitaxel 28Paclitaxel 27durvalumab 26atezolizumab 21Folfox protocol 20Radiotherapy 17Carboplatin 17Taxes 16dehydroftorafur 15Radiation 14Cyclophosphamide 14X-Rays 13Albumin-Bound Paclitaxel 13trastuzumab deruxtecan 12fludarabine 12Surgical Procedures, Operative 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cytochrome P-450 CYP2C8 × Gastrointestinal × 30 days × Clear all
NCT07486713 2026-06-05

Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

Rigel Pharmaceuticals

Phase 4 Recruiting
16 enrolled
CNSGastrointestinalOther hematologic neoplasm

Glioma, Neoplasms, Leukemia, Myeloid, Acute, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡